CTRI/2020/01/022955招募中3 期
Post-operative intraperitoneal chemotherapy after interval cytoreduction in epithelial ovarian cancer (POICE): a randomized phase III trial - POICE
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age >=18 years
- •2. Newly diagnosed stage III/IVa epithelial ovarian, fallopian tube, or peritoneal cancer who received neoadjuvant chemotherapy and completed interval cytoreductive surgery
- •3. Patient should have achieved an optimal cytoreduction status ( largest residue <1 cm) at the time of random allocation
- •4. Patient should be considered fit for random allocation after the surgical procedure is completed
- •5. In case the upfront diagnosis was based on cytology only, the following criteria needs to be satisfied for including the patients for the trial:
- •-Absence of any other known site of cancer
- •-A 125 >= 200
- •-CA 125/CEA ratio > 25
- •-If CA125/CEA is < 25, then there must be available (within 6 weeks of registration) negative colonoscopy and upper GI endoscopy
- •Omental cake or other metastasis > 2 cm in upper abdomen and / or regional LN metastasis by CT/MRI or Ultrasound or laparoscopy
- •6. Primary chemotherapy should have consisted of at least 3 courses and maximum 4 courses of paclitaxel and carboplatin in standard doses.
- •7. ECOG performance status of 0-2 at the time of enrolment in the study
- •8. Negative serum/urine pregnancy test in women of childbearing potential (WOCBP)
- •9. Patients must provide a written informed consent prior to proceeding for surgery for possible randomization.
- •10. Adequate blood counts and organ functions (unless due to chemotherapy) :
- •-Hemoglobin >=8g/dL
- •-WBC counts: 4000-11000/cmm
- •ï?· Platelet counts: >=100,000/cmm
- •-Total Bilirubin<= 1.5 x ULN
- •-AST (SGOT) <= 3 x ULN
- •-ALT (SGPT) <= 3 x ULN
- •-Serum creatinine <= 2 mg/dL or a measured creatinine clearance >= 40 mL/min according to Cockcroft-Gault formula
排除标准
- •1. Serious inter-current illness or medical condition such as active uncontrolled infection, uncontrolled diabetes, or significant cardiac dysfunction that would preclude safe administration of the standard treatment.
- •2. Human Immunodeficiency Virus (HIV) infection/and or Anti-retroviral therapy and or HCV infection (patients who are anti-HCV positive but have been treated and have undetectable viral load would be permitted to be part of the study).
- •3. Active Hepatitis B infection (in patients who are Hepatitis B carriers, the markers of active infection such as HbeAg and HBV DNA titers must be negative and patients would be continued on appropriate prophylaxis with antivirals throughout the duration of the study).
- •4. Pre-existing peripheral neuropathy of > grade 1
- •5. Patients known to have borderline ovarian cancer or low grade ovarian cancer
- •6. Patients who have undergone partial therapy elsewhere will be excluded
- •7. Any intraoperative complications which would render the patient unfit for receiving intraperitoneal chemotherapy
研究者
相似试验
尚未招募
3 期
Chemotherapy inside the abdomen after surgery in patients with ovarian cancer to reduce chances of disease coming backCTRI/2024/08/072237Jawaharlal Institute of Postgraduate Medical Education and Research JIPMER
已完成
不适用
Peri-operative chemotherapy with intraperitoneal and intravenous Paclitaxel plus TS-1 for serosa positive gastric cancer patientsserosa positive gastric cancerJPRN-UMIN000013109Intraperitoneal chemotherapy study group50
已完成
不适用
The role of intra-abdominal chemotherapy in inoperable gastric cancer to change to operable tumorGastric cancer.Malignant neoplasm of stomachIRCT201107257112N1iver and Gastrointestinal Diseases Research Center40
尚未招募
2 期
Determining the efficacy and safety of neoadjuvant IP chemotherapy in rectal cancer patients with the spread of disease in peritoneumCTRI/2023/11/059575Tata Memorial Hospital
进行中（未招募）
1 期
Preoperative intraperitoneal chemotherapy in adjuvant hyperthermiaadjunctive therapy in advanced gastric cancer with high-risk of peritoneal recurrence - a multicentre randomized trialGastric CarcinomaMedDRA version: 21.0Level: LLTClassification code 10007350Term: Carcinoma gastricSystem Organ Class: 100000004864EUCTR2020-001419-25-PLJagiellonian University Medical College600